Proteoliposomes represent a suitable and up to date tool for studying membrane transporters which physiologically mediate absorption, excretion, trafficking and reabsorption of nutrients and metabolites. Using recently developed reconstitution strategies, transporters can be inserted in artificial bilayers with the same orientation as in the cell membranes and in the absence of other interfering molecular systems. These methodologies are very suitable for studying kinetic parameters and molecular mechanisms. After the first applications on mitochondrial transporters, in the last decade, proteoliposomes obtained with optimized methodologies have been used for studying plasma membrane transporters and defining their functional and kinetic properties and structure/function relationships. A lot of information has been obtained which has clarified and completed the knowledge on several transporters among which the OCTN sub-family members, transporters for neutral amino acid, B0AT1 and ASCT2, and others. Transporters can mediate absorption of substrate-like derivatives or drugs, improving their bioavailability or can interact with these compounds or other xenobiotics, leading to side/toxic effects. Therefore, proteoliposomes have recently been used for studying the interaction of some plasma membrane and mitochondrial transporters with toxic compounds, such as mercurials, H 2O 2 and some drugs. Several mechanisms have been defined and in some cases the amino acid residues responsible for the interaction have been identified. The data obtained indicate proteoliposomes as a novel and potentially important tool in drug discovery.
References
[1]
Lahjouji, K.; Mitchell, G.A.; Qureshi, I.A. Carnitine transport by organic cation transporters and systemic carnitine deficiency. Mol. Genet. Metab. 2001, 73, 287–297, doi:10.1006/mgme.2001.3207.
[2]
Chou, J.Y.; Matern, D.; Mansfield, B.C.; Chen, Y.T. Type I glycogen storage diseases: Disorders of the glucose-6-phosphatase complex. Curr. Mol. Med. 2002, 2, 121–143, doi:10.2174/1566524024605798.
[3]
Daniel, H.; Kottra, G. The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflug. Arch. 2004, 447, 610–618, doi:10.1007/s00424-003-1101-4.
[4]
Palmieri, F. Diseases caused by defects of mitochondrial carriers: A review. Biochim. Biophys. Acta 2008, 1777, 564–578, doi:10.1016/j.bbabio.2008.03.008.
[5]
Broer, S.; Palacin, M. The role of amino acid transporters in inherited and acquired diseases. Biochem. J. 2011, 436, 193–211, doi:10.1042/BJ20101912.
[6]
Law, C.J.; Maloney, P.C.; Wang, D.N. Ins and outs of major facilitator superfamily antiporters. Annu. Rev. Microbiol. 2008, 62, 289–305, doi:10.1146/annurev.micro.61.080706.093329.
[7]
Herrera, M.; Garvin, J.L. Aquaporins as gas channels. Pflug. Arch. 2011, 462, 623–630, doi:10.1007/s00424-011-1002-x.
[8]
Forrest, L.R.; Kramer, R.; Ziegler, C. The structural basis of secondary active transport mechanisms. Biochim. Biophys. Acta 2011, 1807, 167–188, doi:10.1016/j.bbabio.2010.10.014.
Hediger, M.A.; Clemencon, B.; Burrier, R.E.; Bruford, E.A. The ABCs of membrane transporters in health and disease (SLC series): Introduction. Mol. Asp. Med. 2013, 34, 95–107, doi:10.1016/j.mam.2012.12.009.
[11]
Nyblom, M.; Oberg, F.; Lindkvist-Petersson, K.; Hallgren, K.; Findlay, H.; Wikstrom, J.; Karlsson, A.; Hansson, O.; Booth, P.J.; Bill, R.M.; et al. Exceptional overproduction of a functional human membrane protein. Protein Expr. Purif. 2007, 56, 110–120, doi:10.1016/j.pep.2007.07.007.
[12]
Wright, E.M.; Loo, D.D.; Hirayama, B.A. Biology of human sodium glucose transporters. Physiol. Rev. 2011, 91, 733–794, doi:10.1152/physrev.00055.2009.
[13]
Wright, E.M. Glucose transport families SLC5 and SLC50. Mol. Asp. Med. 2013, 34, 183–196, doi:10.1016/j.mam.2012.11.002.
[14]
Bodoy, S.; Fotiadis, D.; Stoeger, C.; Kanai, Y.; Palacin, M. The small SLC43 family: Facilitator system l amino acid transporters and the orphan EEG1. Mol. Asp. Med. 2013, 34, 638–645, doi:10.1016/j.mam.2012.12.006.
[15]
Fotiadis, D.; Kanai, Y.; Palacin, M. The SLC3 and SLC7 families of amino acid transporters. Mol. Asp. Med. 2013, 34, 139–158, doi:10.1016/j.mam.2012.10.007.
[16]
Kanai, Y.; Clemencon, B.; Simonin, A.; Leuenberger, M.; Lochner, M.; Weisstanner, M.; Hediger, M.A. The SLC1 high-affinity glutamate and neutral amino acid transporter family. Mol. Asp. Med. 2013, 34, 108–120, doi:10.1016/j.mam.2013.01.001.
[17]
Anderson, C.M.; Stahl, A. SLC27 fatty acid transport proteins. Mol. Asp. Med. 2013, 34, 516–528, doi:10.1016/j.mam.2012.07.010.
[18]
Indiveri, C.; Pochini, L.; Oppedisano, F.; Tonazzi, A. The carnitine transporter network: Interactions with drugs. Curr. Chem. Biol. 2010, 4, 108–123.
[19]
Yonezawa, A.; Inui, K. Novel riboflavin transporter family RFVT/SLC52: Identification, nomenclature, functional characterization and genetic diseases of RFVT/SLC52. Mol. Asp. Med. 2013, 34, 693–701, doi:10.1016/j.mam.2012.07.014.
[20]
Zhao, R.; Goldman, I.D. Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3 and SLC46A1) and folate receptors. Mol. Asp. Med. 2013, 34, 373–385, doi:10.1016/j.mam.2012.07.006.
[21]
Palmieri, F. The mitochondrial transporter family SLC25: Identification, properties and physiopathology. Mol. Asp. Med. 2013, 34, 465–484, doi:10.1016/j.mam.2012.05.005.
[22]
Hirabayashi, Y.; Nomura, K.H.; Nomura, K. The acetyl-CoA transporter family SLC33. Mol. Asp. Med. 2013, 34, 586–589, doi:10.1016/j.mam.2012.05.009.
[23]
Csala, M.; Marcolongo, P.; Lizak, B.; Senesi, S.; Margittai, E.; Fulceri, R.; Magyar, J.E.; Benedetti, A.; Banhegyi, G. Transport and transporters in the endoplasmic reticulum. Biochim. Biophys. Acta 2007, 1768, 1325–1341, doi:10.1016/j.bbamem.2007.03.009.
[24]
Lawal, H.O.; Krantz, D.E. SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol. Asp. Med. 2013, 34, 360–372, doi:10.1016/j.mam.2012.07.005.
[25]
Bobulescu, I.A.; Moe, O.W. Luminal Na(+)/H (+) exchange in the proximal tubule. Pflug. Arch. 2009, 458, 5–21, doi:10.1007/s00424-008-0595-1.
[26]
Forster, I.C.; Hernando, N.; Biber, J.; Murer, H. Phosphate transporters of the SLC20 and SLC34 families. Mol. Asp. Med. 2013, 34, 386–395, doi:10.1016/j.mam.2012.07.007.
Broer, S. Amino acid transport across mammalian intestinal and renal epithelia. Physiol. Rev. 2008, 88, 249–286, doi:10.1152/physrev.00018.2006.
[29]
TransportDB. Available online: http://www.membranetransport.org (accessed on 12 September 2013).
[30]
Indiveri, C.; Galluccio, M.; Scalise, M.; Pochini, L. Strategies of bacterial over expression of membrane transporters relevant in human health: The successful case of the three members of OCTN subfamily. Mol. Biotechnol. 2013, 54, 724–736, doi:10.1007/s12033-012-9586-8.
[31]
Transporter Classification Database. Available online: http://www.tcdb.org/pdb_structure.php (accessed on 12 September 2013).
[32]
Mizuno, N.; Niwa, T.; Yotsumoto, Y.; Sugiyama, Y. Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev. 2003, 55, 425–461, doi:10.1124/pr.55.3.1.
[33]
Sugiura, T.; Kato, Y.; Tsuji, A. Role of SLC xenobiotic transporters and their regulatory mechanisms PDZ proteins in drug delivery and disposition. J. Control. Release 2006, 116, 238–246, doi:10.1016/j.jconrel.2006.06.009.
Han, H.K. Role of transporters in drug interactions. Arch. Pharm. Res. 2011, 34, 1865–1877, doi:10.1007/s12272-011-1107-y.
[36]
DeGorter, M.K.; Xia, C.Q.; Yang, J.J.; Kim, R.B. Drug transporters in drug efficacy and toxicity. Annu. Rev. Pharmacol. Toxicol. 2012, 52, 249–273, doi:10.1146/annurev-pharmtox-010611-134529.
[37]
Mandery, K.; Glaeser, H.; Fromm, M.F. Interaction of innovative small molecule drugs used for cancer therapy with drug transporters. Br. J. Pharmacol. 2012, 165, 345–362, doi:10.1111/j.1476-5381.2011.01618.x.
[38]
Rask-Andersen, M.; Masuram, S.; Fredriksson, R.; Schioth, H.B. Solute carriers as drug targets: Current use, clinical trials and prospective. Mol. Asp. Med. 2013, 34, 702–710, doi:10.1016/j.mam.2012.07.015.
[39]
Giacomini, K.M.; Huang, S.M. Transporters in drug development and clinical pharmacology. Clin. Pharmacol. Ther. 2013, 94, 3–9, doi:10.1038/clpt.2013.86.
[40]
Lounkine, E.; Keiser, M.J.; Whitebread, S.; Mikhailov, D.; Hamon, J.; Jenkins, J.L.; Lavan, P.; Weber, E.; Doak, A.K.; Cote, S.; et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature 2012, 486, 361–367.
[41]
Tsuji, A. Transporter-mediated drug interactions. Drug Metab. Pharmacokinet. 2002, 17, 253–274, doi:10.2133/dmpk.17.253.
[42]
Nakanishi, T.; Tamai, I. Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy. J. Pharm. Sci. 2011, 100, 3731–3750, doi:10.1002/jps.22576.
Macheda, M.L.; Rogers, S.; Best, J.D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol. 2005, 202, 654–662, doi:10.1002/jcp.20166.
[45]
Minchinton, A.I.; Tannock, I.F. Drug penetration in solid tumours. Nat. Rev. Cancer 2006, 6, 583–592, doi:10.1038/nrc1893.
[46]
Okabe, M.; Szakacs, G.; Reimers, M.A.; Suzuki, T.; Hall, M.D.; Abe, T.; Weinstein, J.N.; Gottesman, M.M. Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol. Cancer Ther. 2008, 7, 3081–3091, doi:10.1158/1535-7163.MCT-08-0539.
[47]
Ganapathy, V.; Thangaraju, M.; Prasad, P.D. Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond. Pharmacol. Ther. 2009, 121, 29–40, doi:10.1016/j.pharmthera.2008.09.005.
Oppedisano, F.; Catto, M.; Koutentis, P.A.; Nicolotti, O.; Pochini, L.; Koyioni, M.; Introcaso, A.; Michaelidou, S.S.; Carotti, A.; Indiveri, C. Inactivation of the glutamine/amino acid transporter ASCT2 by 1,2,3-dithiazoles: Proteoliposomes as a tool to gain insights in the molecular mechanism of action and of antitumor activity. Toxicol. Appl. Pharmacol. 2012, 265, 93–102, doi:10.1016/j.taap.2012.09.011.
[50]
Zamek-Gliszczynski, M.J.; Lee, C.A.; Poirier, A.; Bentz, J.; Chu, X.; Ellens, H.; Ishikawa, T.; Jamei, M.; Kalvass, J.C.; Nagar, S.; et al. ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clin. Pharmacol. Ther. 2013, 94, 64–79, doi:10.1038/clpt.2013.45.
[51]
Hillgren, K.M.; Keppler, D.; Zur, A.A.; Giacomini, K.M.; Stieger, B.; Cass, C.E.; Zhang, L. Emerging transporters of clinical importance: An update from the international transporter consortium. Clin. Pharmacol. Ther. 2013, 94, 52–63, doi:10.1038/clpt.2013.74.
[52]
Huang, S.M.; Strong, J.M.; Zhang, L.; Reynolds, K.S.; Nallani, S.; Temple, R.; Abraham, S.; Habet, S.A.; Baweja, R.K.; Burckart, G.J.; et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol. 2008, 48, 662–670, doi:10.1177/0091270007312153.
[53]
Zhang, L.; Zhang, Y.; Huang, S.M. Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: Challenges in predicting drug interactions. Mol. Pharm. 2009, 6, 1766–1774, doi:10.1021/mp900132e.
[54]
Agarwal, S.; Chinn, L.; Zhang, L. An overview of transporter information in package inserts of recently approved new molecular entities. Pharm. Res. 2013, 30, 899–910, doi:10.1007/s11095-012-0924-0.
[55]
Guidotti, G.G.; Luneburg, B.; Borghetti, A.F. Amino acid uptake in isolated chick embryo heart cells. Biochem. J. 1969, 114, 97–105.
[56]
Palmieri, F.; Klingenberg, M. Direct methods for measuring metabolite transport and distribution in mitochondria. Methods Enzymol. 1979, 56, 279–301, doi:10.1016/0076-6879(79)56029-7.
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Drug Interaction Studies—Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Clin. Pharmacol. 2012, 1–79.
[59]
Pochini, L.; Scalise, M.; Galluccio, M.; Indiveri, C. OCTN cation transporters in health and disease: Role as drug targets and assay development. J. Biomol. Screen. 2013, doi:10.1177/1087057113493006.
[60]
Whorton, M.R.; MacKinnon, R. Crystal structure of the mammalian GIRK2 K+ channel and gating regulation by G proteins, PIP2, and sodium. Cell 2011, 147, 199–208, doi:10.1016/j.cell.2011.07.046.
[61]
Brohawn, S.G.; del Marmol, J.; MacKinnon, R. Crystal structure of the human K2P TRAAK, a lipid- and mechano-sensitive K+ ion channel. Science 2012, 335, 436–441, doi:10.1126/science.1213808.
[62]
Miller, A.N.; Long, S.B. Crystal structure of the human two-pore domain potassium channel K2P1. Science 2012, 335, 432–436, doi:10.1126/science.1213274.
[63]
Song, C.; Weichbrodt, C.; Salnikov, E.S.; Dynowski, M.; Forsberg, B.O.; Bechinger, B.; Steinem, C.; de Groot, B.L.; Zachariae, U.; Zeth, K. Crystal structure and functional mechanism of a human antimicrobial membrane channel. Proc. Natl. Acad. Sci. USA 2013, 110, 4586–4591, doi:10.1073/pnas.1214739110.
[64]
Gregoriadis, G.; Ryman, B.E. Liposomes as carriers of enzymes or drugs: A new approach to the treatment of storage diseases. Biochem. J. 1971, 124, 58P.
[65]
Gregoriadis, G. The carrier potential of liposomes in biology and medicine (first of two parts). N. Engl. J. Med. 1976, 295, 704–710, doi:10.1056/NEJM197609232951305.
[66]
Gregoriadis, G. The carrier potential of liposomes in biology and medicine (second of two parts). N. Engl. J. Med. 1976, 295, 765–770, doi:10.1056/NEJM197609302951406.
[67]
Boddapati, S.V.; D’Souza, G.G.; Weissig, V. Liposomes for drug delivery to mitochondria. Methods Mol. Biol. 2010, 605, 295–303, doi:10.1007/978-1-60327-360-2_20.
[68]
Kasahara, M.; Hinkle, P.C. Reconstitution of D-glucose transport catalyzed by a protein fraction from human erythrocytes in sonicated liposomes. Proc. Nat. Acad. Sci. USA 1976, 73, 396–400, doi:10.1073/pnas.73.2.396.
[69]
Kasahara, M.; Hinkle, P.C. Reconstitution and purification of the D-glucose transporter from human erythrocytes. J. Biol. Chem. 1977, 252, 7384–7390.
[70]
Newman, M.J.; Foster, D.L.; Wilson, T.H.; Kaback, H.R. Purification and reconstitution of functional lactose carrier from Escherichia coli. J. Biol. Chem. 1981, 256, 11804–11808.
[71]
Viitanen, P.; Garcia, M.L.; Kaback, H.R. Purified reconstituted lac carrier protein from Escherichia coli is fully functional. Proc. Natl. Acad. Sci. USA 1984, 81, 1629–1633, doi:10.1073/pnas.81.6.1629.
[72]
Kramer, R.; Klingenberg, M. Reconstitution of adenine nucleotide transport from beef heart mitochondria. Biochemistry 1979, 18, 4209–4215, doi:10.1021/bi00586a027.
[73]
Ueno, M.; Tanford, C.; Reynolds, J.A. Phospholipid vesicle formation using nonionic detergents with low monomer solubility. Kinetic factors determine vesicle size and permeability. Biochemistry 1984, 23, 3070–3076, doi:10.1021/bi00308a034.
[74]
Kramer, R.; Heberger, C. Functional reconstitution of carrier proteins by removal of detergent with a hydrophobic ion exchange column. Biochim. Biophys. Acta 1986, 863, 289–296, doi:10.1016/0005-2736(86)90269-5.
[75]
Palmieri, F.; Indiveri, C.; Bisaccia, F.; Iacobazzi, V. Mitochondrial metabolite carrier proteins: Purification, reconstitution, and transport studies. Methods Enzymol. 1995, 260, 349–369, doi:10.1016/0076-6879(95)60150-3.
[76]
Klingenberg, M.; Winkler, E. The reconstituted isolated uncoupling protein is a membrane potential driven H+ translocator. EMBO J. 1985, 4, 3087–3092.
[77]
Spagnoletta, A.; de Palma, A.; Prezioso, G.; Scalera, V. A micro-batchwise technique method for rapid reconstitution of functionally active mitochondrial ADP/ATP carrier from Jerusalem artichoke (Helianthus tuberosus L.) tubers. J. Biochem. Biophys. Methods 2008, 70, 954–957, doi:10.1016/j.jprot.2007.11.003.
[78]
Pochini, L.; Scalise, M.; Galluccio, M.; Amelio, L.; Indiveri, C. Reconstitution in liposomes of the functionally active human OCTN1 (SLC22A4) transporter overexpressed in Escherichia coli. Biochem. J. 2011, 439, 227–233, doi:10.1042/BJ20110544.
[79]
Indiveri, C. Studying amino acid transport using liposomes. Methods Mol. Biol. 2010, 606, 55–68, doi:10.1007/978-1-60761-447-0_5.
[80]
Rigaud, J.L.; Levy, D. Reconstitution of membrane proteins into liposomes. Methods Enzymol. 2003, 372, 65–86, doi:10.1016/S0076-6879(03)72004-7.
[81]
Klingenberg, M. Molecular aspects of the adenine nucleotide carrier from mitochondria. Arch. Biochem. Biophys. 1989, 270, 1–14, doi:10.1016/0003-9861(89)90001-5.
[82]
Palmieri, F.; Indiveri, C.; Bisaccia, F.; Kramer, R. Functional properties of purified and reconstituted mitochondrial metabolite carriers. J. Bioenerg. Biomembr. 1993, 25, 525–535, doi:10.1007/BF01108409.
[83]
Palmieri, F. Mitochondrial carrier proteins. FEBS Lett. 1994, 346, 48–54, doi:10.1016/0014-5793(94)00329-7.
[84]
Vickers, M.F.; Mani, R.S.; Sundaram, M.; Hogue, D.L.; Young, J.D.; Baldwin, S.A.; Cass, C.E. Functional production and reconstitution of the human equilibrative nucleoside transporter (hENT1) in Saccharomyces cerevisiae. Interaction of inhibitors of nucleoside transport with recombinant hENT1 and a glycosylation-defective derivative (hENT1/N48Q). Biochem. J. 1999, 339, 21–32, doi:10.1042/0264-6021:3390021.
[85]
Quick, M.; Wright, E.M. Employing Escherichia coli to functionally express, purify, and characterize a human transporter. Proc. Natl. Acad. Sci. USA 2002, 99, 8597–8601, doi:10.1073/pnas.132266599.
[86]
Komatsu, T.; Hiasa, M.; Miyaji, T.; Kanamoto, T.; Matsumoto, T.; Otsuka, M.; Moriyama, Y.; Omote, H. Characterization of the human MATE2 proton-coupled polyspecific organic cation exporter. Int. J. Biochem. Cell Biol. 2011, 43, 913–918, doi:10.1016/j.biocel.2011.03.005.
[87]
Filippo, C.A.; Ardon, O.; Longo, N. Glycosylation of the OCTN2 carnitine transporter: Study of natural mutations identified in patients with primary carnitine deficiency. Biochim. Biophys. Acta 2011, 1812, 312–320, doi:10.1016/j.bbadis.2010.11.007.
[88]
Keller, T.; Schwarz, D.; Bernhard, F.; Dotsch, V.; Hunte, C.; Gorboulev, V.; Koepsell, H. Cell free expression and functional reconstitution of eukaryotic drug transporters. Biochemistry 2008, 47, 4552–4564, doi:10.1021/bi800060w.
[89]
Pochini, L.; Oppedisano, F.; Indiveri, C. Reconstitution into liposomes and functional characterization of the carnitine transporter from renal cell plasma membrane. Biochim. Biophys. Acta 2004, 1661, 78–86, doi:10.1016/j.bbamem.2003.12.001.
[90]
Oppedisano, F.; Pochini, L.; Galluccio, M.; Cavarelli, M.; Indiveri, C. Reconstitution into liposomes of the glutamine/amino acid transporter from renal cell plasma membrane: Functional characterization, kinetics and activation by nucleotides. Biochim. Biophys. Acta 2004, 1667, 122–131, doi:10.1016/j.bbamem.2004.09.007.
[91]
Oppedisano, F.; Indiveri, C. Reconstitution into liposomes of the B degrees -like glutamine-neutral amino acid transporter from renal cell plasma membrane. Biochim. Biophys. Acta 2008, 1778, 2258–2265, doi:10.1016/j.bbamem.2008.05.011.
[92]
Oppedisano, F.; Pochini, L.; Galluccio, M.; Indiveri, C. The glutamine/amino acid transporter (ASCT2) reconstituted in liposomes: Electrical nature of the glutamine/glutamate antiport. Ital. J. Biochem. 2007, 56, 275–278.
[93]
Oppedisano, F.; Pochini, L.; Broer, S.; Indiveri, C. The B0AT1 amino acid transporter from rat kidney reconstituted in liposomes: Kinetics and inactivation by methylmercury. Biochim. Biophys. Acta 2011, 1808, 2551–2558, doi:10.1016/j.bbamem.2011.05.011.
[94]
Mouro-Chanteloup, I.; Cochet, S.; Chami, M.; Genetet, S.; Zidi-Yahiaoui, N.; Engel, A.; Colin, Y.; Bertrand, O.; Ripoche, P. Functional reconstitution into liposomes of purified human RhCG ammonia channel. PLoS One 2010, 5, e8921, doi:10.1371/journal.pone.0008921.
[95]
Scalise, M.; Galluccio, M.; Pochini, L.; Indiveri, C. Over-expression in Escherichia coli, purification and reconstitution in liposomes of the third member of the OCTN sub-family: The mouse carnitine transporter OCTN3. Biochem. Biophys. Res. Commun. 2012, 422, 59–63, doi:10.1016/j.bbrc.2012.04.105.
[96]
Pingitore, P.; Pochini, L.; Scalise, M.; Galluccio, M.; Hedfalk, K.; Indiveri, C. Large scale production of the active human ASCT2 (SLC1A5) transporter in Pichia pastoris—Functional and kinetic asymmetry revealed in proteoliposomes. Biochim. Biophys. Acta 2013, 1828, 2238–2246, doi:10.1016/j.bbamem.2013.05.034.
[97]
Song, P.; Rekow, S.S.; Singleton, C.A.; Sekhon, H.S.; Dissen, G.A.; Zhou, M.; Campling, B.; Lindstrom, J.; Spindel, E.R. Choline transporter-like protein 4 (CTL4) links to non-neuronal acetylcholine synthesis. J. Neurochem. 2013, 126, 451–461, doi:10.1111/jnc.12298.
[98]
Pochini, L.; Scalise, M.; Galluccio, M.; Pani, G.; Siminovitch, K.A.; Indiveri, C. The human OCTN1 (SLC22A4) reconstituted in liposomes catalyzes acetylcholine transport which is defective in the mutant L503F associated to the Crohn’s disease. Biochim. Biophys. Acta 2012, 1818, 559–565, doi:10.1016/j.bbamem.2011.12.014.
[99]
Verchere, A.; Broutin, I.; Picard, M. Photo-induced proton gradients for the in vitro investigation of bacterial efflux pumps. Sci. Rep. 2012, 2, 306.
[100]
Raunser, S.; Haase, W.; Bostina, M.; Parcej, D.N.; Kuhlbrandt, W. High-yield expression, reconstitution and structure of the recombinant, fully functional glutamate transporter GLT-1 from Rattus norvegicus. J. Mol. Biol. 2005, 351, 598–613, doi:10.1016/j.jmb.2005.06.036.
[101]
Adam, Y.; Edwards, R.H.; Schuldiner, S. Expression and function of the rat vesicular monoamine transporter 2. Am. J. Physiol. Cell Physiol. 2008, 294, C1004–C1011, doi:10.1152/ajpcell.00348.2007.
[102]
Tonazzi, A.; Indiveri, C. Chemical modification of the mitochondrial ornithine/citrulline carrier by SH reagents: Effects on the transport activity and transition from carrier to pore-like function. Biochim. Biophys. Acta 2003, 1611, 123–130, doi:10.1016/S0005-2736(03)00033-6.
[103]
Indiveri, C.; Tonazzi, A.; Dierks, T.; Kramer, R.; Palmieri, F. The mitochondrial carnitine carrier: Characterization of SH-groups relevant for its transport function. Biochim. Biophys. Acta. 1992, 1140, 53–58, doi:10.1016/0005-2728(92)90019-X.
[104]
Tonazzi, A.; Indiveri, C. Effects of heavy metal cations on the mitochondrial ornithine/citrulline transporter reconstituted in liposomes. Biometals 2011, 24, 1205–1215, doi:10.1007/s10534-011-9479-5.
[105]
Tonazzi, A.; Console, L.; Indiveri, C. Inhibition of mitochondrial carnitine/acylcarnitine transporter by H2O2: Molecular mechanism and possible implication in pathophysiology. Chem. Biol. Interact. 2013, 203, 423–439, doi:10.1016/j.cbi.2013.01.006.
[106]
Pochini, L.; Galluccio, M.; Scumaci, D.; Giangregorio, N.; Tonazzi, A.; Palmieri, F.; Indiveri, C. Interaction of beta-lactam antibiotics with the mitochondrial carnitine/acylcarnitine transporter. Chem. Biol. Interact. 2008, 173, 187–194, doi:10.1016/j.cbi.2008.03.003.
[107]
Oppedisano, F.; Fanello, D.; Calvani, M.; Indiveri, C. Interaction of mildronate with the mitochondrial carnitine/acylcarnitine transport protein. J. Biochem. Mol. Toxicol. 2008, 22, 8–14, doi:10.1002/jbt.20208.
[108]
Agency for Toxic Substance and Disease Registry (ATSDR). Toxicological Profile for Mercury; Department of Health and Humans Services, Public Health Services, Centers for Disease Control: Atlanta, GA, USA, 1999.
[109]
Van Iwaarden, P.R.; Driessen, A.J.; Konings, W.N. What we can learn from the effects of thiol reagents on transport proteins. Biochim. Biophys. Acta 1992, 1113, 161–170, doi:10.1016/0304-4157(92)90037-B.
[110]
Oppedisano, F.; Galluccio, M.; Indiveri, C. Inactivation by Hg2+ and methylmercury of the glutamine/amino acid transporter (ASCT2) reconstituted in liposomes: Prediction of the involvement of a CXXC motif by homology modelling. Biochem. Pharmacol. 2010, 80, 1266–1273, doi:10.1016/j.bcp.2010.06.032.
[111]
Jordan, I.K.; Kondrashov, F.A.; Adzhubei, I.A.; Wolf, Y.I.; Koonin, E.V.; Kondrashov, A.S.; Sunyaev, S. A universal trend of amino acid gain and loss in protein evolution. Nature 2005, 433, 633–638, doi:10.1038/nature03306.
[112]
Abajian, C.; Rosenzweig, A.C. Crystal structure of yeast Sco1. J. Biol. Inorg. Chem. 2006, 11, 459–466, doi:10.1007/s00775-006-0096-7.
[113]
Pochini, L.; Peta, V.; Indiveri, C. Inhibition of the OCTN2 carnitine transporter by HgCl2 and methylmercury in the proteoliposome experimental model: Insights in the mechanism of toxicity. Toxicol. Mech. Methods 2013, 23, 68–76, doi:10.3109/15376516.2012.719166.
[114]
Pochini, L.; Scalise, M.; Indiveri, C. Inactivation by omeprazole of the carnitine transporter (OCTN2) reconstituted in liposomes. Chem. Biol. Interact. 2009, 179, 394–401, doi:10.1016/j.cbi.2008.10.052.
Shin, J.M.; Cho, Y.M.; Sachs, G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J. Am. Chem. Soc. 2004, 126, 7800–7811, doi:10.1021/ja049607w.
Indiveri, C.; Tonazzi, A.; Palmieri, F. Identification and purification of the ornithine/citrulline carrier from rat liver mitochondria. Eur. J. Biochem. 1992, 207, 449–454, doi:10.1111/j.1432-1033.1992.tb17070.x.
[120]
Tonazzi, A.; Giangregorio, N.; Indiveri, C.; Palmieri, F. Identification by site-directed mutagenesis and chemical modification of three vicinal cysteine residues in rat mitochondrial carnitine/acylcarnitine transporter. J. Biol. Chem. 2005, 280, 19607–19612, doi:10.1074/jbc.M411181200.
Camacho, J.A.; Obie, C.; Biery, B.; Goodman, B.K.; Hu, C.A.; Almashanu, S.; Steel, G.; Casey, R.; Lambert, M.; Mitchell, G.A.; et al. Hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome is caused by mutations in a gene encoding a mitochondrial ornithine transporter. Nat. Genet. 1999, 22, 151–158, doi:10.1038/9658.
[123]
Schroder, E.; Eaton, P. Hydrogen peroxide as an endogenous mediator and exogenous tool in cardiovascular research: Issues and considerations. Curr. Opin. Pharmacol. 2008, 8, 153–159, doi:10.1016/j.coph.2007.12.012.
[124]
Bae, Y.S.; Oh, H.; Rhee, S.G.; Yoo, Y.D. Regulation of reactive oxygen species generation in cell signaling. Mol. Cells 2011, 32, 491–509, doi:10.1007/s10059-011-0276-3.
[125]
Indiveri, C.; Tonazzi, A.; Stipani, I.; Palmieri, F. The purified and reconstituted ornithine/citrulline carrier from rat liver mitochondria: Electrical nature and coupling of the exchange reaction with H+ translocation. Biochem. J. 1997, 15, 349–355.
[126]
Indiveri, C.; Tonazzi, A.; Stipani, I.; Palmieri, F. The purified and reconstituted ornithine/citrulline carrier from rat liver mitochondria catalyses a second transport mode: Ornithine+/H+ exchange. Biochem. J. 1999, 341, 705–711, doi:10.1042/0264-6021:3410705.
